Pfizer Inc.

NYSE:PFE   3:59:58 PM EDT
43.17
+0.01 (+0.02%)
5:25:18 PM EDT: $43.14 -0.03 (-0.07%)
Products, Regulatory, Earnings Announcements

Valneva, Pfizer Update On Phase 2 Results For Lyme Disease Vaccine Candidate

Published: 09/28/2021 05:19 GMT
Pfizer Inc. (PFE) - Reg-valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate.
Vla15 Was Safe and Well-tolerated Across All Doses and Age Groups Tested.
No Related Serious Adverse Events (saes) Were Observed in Any Treatment Group.
Vla15's Acceptable Safety Profile Was Confirmed Through One-month Post-booster.
And Pfizer Announced Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate Vla15.
Study is Continuing to Monitor Persistence of Antibody Responses.
Excited by These Additional Phase 2 Results, Which We Believe Take US a Step Closer to Major Contribution Against This Severe Disease, Subject to Approval.
Pfizer Exec: These Positive Results of Phase 2 Vla15-202 Study Represent Another Important Milestone in Development of Vla15.
Further Company Coverage: .
(gdansk Newsroom).
((gdansk.
Newsroom@thomsonreuters.
Com; +48 58 778 51 10;)).
Revenue is expected to be $22.81 Billion
Adjusted EPS is expected to be $1.08

Next Quarter Revenue Guidance is expected to be $24.98 Billion
Next Quarter EPS Guidance is expected to be $1.05

More details on our Analysts Page.